Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.55 |
| ▸ | CA9 | Q16790 | 12/20 | 0.55 |
| ▸ | CA1 | P00915 | 11/20 | 0.55 |
| ▸ | CA12 | O43570 | 8/20 | 0.55 |
| ▸ | CA7 | P43166 | 5/20 | 0.55 |
| ▸ | CA6 | P23280 | 4/20 | 0.55 |
| ▸ | CA5A | P35218 | 4/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.55 |
| ▸ | CA4 | P22748 | 3/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.55 |
| ▸ | CA3 | P07451 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524384 | 0.84 | ALDH1A1 (0.50) | CA2CA9CA1CA12CA7 | |
| SCHEMBL394533 | 0.83 | LMNA (0.49) | LMNAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL29421567 | 0.83 | LMNA (0.49) | LMNAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL878966 | 0.83 | CA2 (0.67) | CA2CA9CA1CA12CA7 | |
| SCHEMBL30291216 | 0.83 | CA2 (0.67) | CA2CA9CA1CA12CA7 | |
| SCHEMBL1368195 | 0.83 | CA2 (0.61) | CA2CA9CA1CA12CA7 | |
| SCHEMBL233320 | 0.82 | LMNA (0.61) | CA2CA9CA1CA12CA7 | |
| SCHEMBL29365636 | 0.82 | LMNA (0.61) | CA2CA9CA1CA12CA7 | |
| SCHEMBL830828 | 0.81 | LMNA (0.51) | CA2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL17985 | 0.81 | LMNA (0.47) | CA2CA9CA1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | NXERA PHARMA UK LIMITED (GB) | 2025-12-09 | — | — | US | disclosed |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | NXERA PHARMA UK LIMITED (GB) | 2025-06-05 | — | — | US | disclosed |
| CN-119855814-A | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP 4) agonists for the treatment of gastrointestinal and pulmonary diseases | 奈克斯拉制药英国有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4532491-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| CN-119790036-A | Pyrrolidine-2-carboxamide derivatives as prostaglandin E2 receptor 4 (EP 4) agonists for the treatment of gastrointestinal and pulmonary diseases | 奈克斯拉制药英国有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| CN-119654310-A | 1, 2-Substituted 3-oxo-pyrazolidine derivatives as prostaglandin E2 receptor 4 (EP 4) agonists for the treatment of gastrointestinal and pulmonary diseases | 奈克斯拉制药英国有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-3746437-B1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2024-08-21 | — | — | EP | disclosed |
| US-20240116931-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2024-04-11 | — | — | US | disclosed |
| WO-2024028604-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| CN-1906183-A | N-acylsulfonamide apoptosis promoters | ABBOTT LAB (US) | 2007-01-31 | — | — | CN | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| EP-1685119-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | CA2 3537/4885CA9 4554/4885CA1 2869/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | CA2 3537/4885CA9 4554/4885CA1 2869/4885 |
| US-12492174-B2 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | PTGER4, PTGER1, PTGER2 | CA2 1914/4885CA9 4490/4885CA1 4689/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | CA2 3537/4885CA9 4554/4885CA1 2869/4885 |
| US-20240116931-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | MAPK4, MAP3K4, MAP4K1 | CA2 4640/4885CA9 4729/4885CA1 3490/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | CA2 4218/4885CA9 4538/4885CA1 3146/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | CA2 2210/4885CA9 4004/4885CA1 3170/4885 |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | CA2 4640/4885CA9 4729/4885CA1 3490/4885 |
| US-20250179036-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | PTGER4, PTGER1, PTGER2 | CA2 1914/4885CA9 4490/4885CA1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.